Omalizumab (Xolair®)

DRUG3 trials

Sponsors

Technical University of Munich, BioRay Pharmaceutical Co., Ltd., Johns Hopkins University

Conditions

AllergiesAtopic DermatitisAtopic EczemaChronic Obstructive Pulmonary Disease (COPD)Similarity of Pharmacokinetics and Safety

Phase 1

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

TerminatedNCT04361812

BioRay Pharmaceutical Co., Ltd.Similarity of Pharmacokinetics and Safety

Start: 2020-10-15End: 2021-12-31Updated: 2025-11-21

Phase 2

Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

CompletedNCT01179529

Technical University of MunichAtopic Dermatitis, Atopic Eczema

Updated: 2012-01-10

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

RecruitingNCT07059091

Johns Hopkins UniversityAllergies, Chronic Obstructive Pulmonary Disease (COPD)

Start: 2026-02-12End: 2031-05-01Target: 334Updated: 2026-02-17